Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 1, 2012, Pages 75-86

  Miyamoto, S ^a   Ito, K ^a   Miyakubo, M ^a   Suzuki, R ^a   Yamamoto, T ^a   Suzuki, K ^a,b   Yamanaka, H ^c  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Geriatrics Research Institute   (Japan)

^c Kurosawa Hospital   (Japan)

Author keywords

Gleason score; hormonal therapy; metastasis; PSA

Indexed keywords

ALKALINE PHOSPHATASE; ESTROGEN DERIVATIVE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; STEROID; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISTANT METASTASIS; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SURVIVAL TIME; TESTOSTERONE BLOOD LEVEL; TUMOR DIFFERENTIATION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BIOPSY; BONE NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PALLIATIVE CARE; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84857064502     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.47     Document Type: Article

References (32)

1. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, OberaignerWet al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008; 101: 809-816. (Pubitemid 351347736)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Ito K, Yamamoto T, Takechi H, Suzuki K. Impact of exposure rate of PSA-screening on clinical stage of prostate cancer in Japan. J Urol 2006; 175 (Suppl): 477-478.
4. Cancer statistics in Japan 2010. Number of Deaths, by Cancer Site (2008/2009).
5. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005; 12: 46-61.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. (Pubitemid 39315317)
7. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. (Pubitemid 39315318)
8. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-1446.
9. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
10. Dreicer R, Agus DB, MacVicar GR, MacLean D, Zhang T, Stadler WM. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, openlabel study. American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). San Francisco, CA,March 5-7, 2010.
11. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
12. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364: 2055-2058.
13. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202. (Pubitemid 18023133)
14. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Sur Pathol 2005; 29: 1228-1242. (Pubitemid 41232997)
15. Cooper EH, Armitage TG, Robinson MR, Newling DW, Richards BR, Smith PH et al. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 1990; 66 (5 Suppl): 1025-1028. (Pubitemid 20293000)
16. Imai K, Tomaru Y, Ohnuki T, Yamanaka H, Sakai H, Kanetake H et al. Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis. Cancer 1992; 69: 2983-2989.
17. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-2101. (Pubitemid 40617061)
18. Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrle R et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol 2005; 23: 2911-2917. (Pubitemid 46224109)
19. Collette L, de Reijke TM, Schröder FH. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 2003; 44: 182-189. (Pubitemid 36917001)
20. Furuya Y, Akakura K, Tobe T, Ichikawa T, Igarashi T, Ito H. Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment. Int Urol Nephrol 2001; 32: 659-663. (Pubitemid 34272331)
21. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002; 168: 995-1000.
22. Benaim EA, Pace CM, Lam PM, Roehrborn CG. Nadir prostatespecific antigen as a predictor of progression to androgenindependent prostate cancer. Urology 2002; 59: 73-78. (Pubitemid 34059310)
23. Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Nadir prostate-specific antigen best predicts the progression to androgen- independent prostate cancer. Int J Cancer 2004; 108: 877-881. (Pubitemid 38112617)
24. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005; 23: 6556-6560. (Pubitemid 46190248)
25. Robinson D, Sandblom G, Johansson R, Garmo H, Aus G, Hedlund PO et al. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer. Urology 2008; 72: 903-907.
26. Daskivich TJ, Regan MM, Oh WK. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology 2007; 70: 527-531. (Pubitemid 47464497)
27. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009; 27: 2450-2456.
28. Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S, Kanetake H et al. Bicalutamide 80 mg combined with a luteinizing hormonereleasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis 2007; 10: 194-201. (Pubitemid 46881672)
29. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL et al. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. Urology 1996; 47 (1A Suppl): 54-60. (Pubitemid 126691287)
30. Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004; 34: 20-28. (Pubitemid 43115330)
31. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-1498.
32. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042. (Pubitemid 28457865)